We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.06B
AUM Growth
-$215M
Cap. Flow
-$288M
Cap. Flow %
-5.68%
Top 10 Hldgs %
52.55%
Holding
152
New
45
Increased
20
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$94.3M
2
PFE icon
Pfizer
PFE
+$87.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$79.4M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$38.7M
5
INSM icon
Insmed
INSM
+$35M

Top Sells

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$121M
2
ACH
Accendra Health
ACH
+$64.2M
3
ALHC icon
Alignment Healthcare
ALHC
+$40.8M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$38.8M
5
BCAX
Bicara Therapeutics
BCAX
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.22%
2 Real Estate 0.01%
3 Technology 0.01%
4 Consumer Discretionary 0.01%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$1.28B 25.19%
17,991,024
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$209M 4.13%
23,991,594
-4,442
-0% -$46.6K
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$165M 3.25%
1,489,000
+627,000
+73% +$79.4M
CNC icon
4
Centene
CNC
$32.8B
$162M 3.2%
2,671,921
– –
OSCR icon
5
Oscar Health
OSCR
$8.77B
$155M 3.07%
11,840,818
+5,818
+0% +$86.4K
MRUS
6
DELISTED
Merus
MRUS
$134M 2.64%
3,173,928
+201,141
+7% +$8.77M
SPRY icon
7
ARS Pharmaceuticals
SPRY
$695M
$132M 2.61%
10,514,657
– –
RVMD icon
8
Revolution Medicines
RVMD
$39.6B
$117M 2.32%
3,317,332
+59,000
+2% +$2.39M
AHCO icon
9
AdaptHealth
AHCO
$1.49B
$105M 2.08%
9,711,410
– –
INDV icon
10
Indivior Pharmaceuticals
INDV
$4.79B
$101M 1.99%
10,567,160
+1,684,000
+19% +$17.7M
BKD icon
11
Brookdale Senior Living
BKD
$3.58B
$97.7M 1.93%
15,612,264
– –
ALHC icon
12
Alignment Healthcare
ALHC
$4.26B
$85M 1.68%
4,567,473
-2,736,829
-37% -$40.8M
UTHR icon
13
United Therapeutics
UTHR
$22.7B
$84.8M 1.68%
+275,226
New +$94.3M
PFE icon
14
Pfizer
PFE
$143B
$84.8M 1.67%
+3,347,296
New +$87.6M
NAMS icon
15
NewAmsterdam Pharma
NAMS
$3.7B
$84M 1.66%
4,103,957
-210,383
-5% -$4.68M
CPRX
16
DELISTED
Catalyst Pharmaceutical
CPRX
$83M 1.64%
3,422,149
+289,138
+9% +$6.51M
DVAX
17
DELISTED
Dynavax Technologies
DVAX
$67.3M 1.33%
5,191,493
-2,330
-0% -$30.8K
BAX icon
18
Baxter International
BAX
$11.7B
$65.8M 1.3%
1,923,100
– –
LEGN icon
19
Legend Biotech
LEGN
$4.31B
$59.2M 1.17%
1,743,555
+191,837
+12% +$6.88M
BIO icon
20
Bio-Rad Laboratories Class A
BIO
$8.15B
$55.1M 1.09%
226,070
+74,426
+49% +$22.4M
IDYA icon
21
IDEAYA Biosciences
IDYA
$3.47B
$53.5M 1.06%
3,267,551
+531,551
+19% +$11.3M
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.28B
$45.7M 0.9%
2,078,509
– –
LRMR icon
23
Larimar Therapeutics
LRMR
$384M
$45.6M 0.9%
21,231,974
– –
EHAB
24
DELISTED
Enhabit
EHAB
$43.9M 0.87%
4,997,746
-13,226
-0.3% -$111K
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$35.7B
$39.2M 0.77%
145,000
-191
-0.1% -$49.1K
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2025 Portfolio in Review

As of Q1 2025, Deerfield Management held 152 positions worth $5.06B, down 4.1% from $5.28B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $288M in Q1 2025, closing 29 positions and reducing 17 holdings. Its most notable exit was Waystar Holding Corp, an estimated $121M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate and Technology.

Against the trend, Deerfield Management opened a new position in United Therapeutics worth $84.8M.

  • Deerfield Management's largest Q1 2025 buy was United Therapeutics: 275,226 shares worth $84.8M.
  • Deerfield Management added most to Neurocrine Biosciences in Q1 2025, an estimated $79.4M increase.
  • Deerfield Management's biggest Q1 2025 reduction was Alignment Healthcare, cutting an estimated $40.8M.
  • Deerfield Management fully exited Waystar Holding Corp in Q1 2025, selling an estimated $121M.
  • Deerfield Management's ten largest holdings make up 53% of its $5.06B portfolio in Q1 2025.
  • Deerfield Management opened 45 new positions and closed 29 in Q1 2025.
  • Deerfield Management's portfolio value fell 4.1% quarter-over-quarter to $5.06B.

Based on Deerfield Management's 13F filing for Q1 2025, filed 15 May 2025.